Research programme: LRRK2 inhibitors - Denali Therapeutics/Genentech
Latest Information Update: 16 May 2021
At a glance
- Originator Genentech
- Developer Denali Therapeutics Inc
- Class Antiparkinsonians; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 01 May 2021 Preclinical trials in Parkinson's disease in USA (unspecified route)
- 28 Sep 2020 No recent reports of development identified for research development in Parkinson's-disease in USA
- 25 Aug 2016 Early research in Parkinson's disease in USA (unspecified route)